Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin-alpha and IV Iron Post-HSCT
NCT00557817Phase 3Completed
- Sponsor
- University of Liège
- Start
- Mar 2004
- Primary completion
- Aug 2008
- Modality
- Erythropoietins, Colony Stimulating Factors, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa and iron sucrose in anemia (3 arms), sponsored by University of Liège. Primary endpoints: Median time to achieve hemoglobin (Hb) level > 13 g/dL at 126 days and Proportion of complete correctors (Hb > 13 g/dL) at 126 days. Started Mar 2004; status: completed.
02
Drugs
darbepoetin alfairon sucrose
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00557817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557817.